Comment from Unlearn.AI

Summary: Unlearn.AI, Inc., a company developing machine learning methods for clinical trials, supports the draft guidance on Master Protocols. They advocate for the inclusion of specific, standardized evaluation approaches for innovative methods like AI/ML and Bayesian designs to foster trust and stimulate innovation.